Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

Successful Early Access Program results in purchase orders for 10 systems and installations at 6 institutions in 2023 FREMONT, Calif., Jan. 4, 2024 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the…

Click here to view original post